Login / Signup

TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer.

David B RosenAnne Månsson KvarnhammarBurkhardt LauferThomas KnappeJens Jakob KarlssonEnping HongYu-Chi LeeDhruv ThakarLuis Alejandro ZúñigaKathy BangSimran Singh SabharwalKaran UppalJanne Damm OllingKristian KjaergaardThomas KurpiersMeike SchnabelDiana ReichPhilipp GlockJoachim ZettlerMathias KruschAna BernhardStefan HeinigValentino KonjikThomas WeggeYvonne HehnSteffen KillianLaura VietJosefine RunzFrank FaltingerMohammad TabriziKristin Laura AbelVibeke Miller BreinholtStina M SingelKennett SprogøeJuha Punnonen
Published in: Journal for immunotherapy of cancer (2022)
TransCon IL-2 β/γ is a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2. It has remarkable and durable pharmacodynamic effects in monkeys and potential for improved clinical efficacy and tolerability compared with aldesleukin. TransCon IL-2 β/γ is currently being evaluated in a Phase 1/2 clinical trial (NCT05081609).
Keyphrases
  • clinical trial
  • randomized controlled trial
  • squamous cell carcinoma
  • open label
  • cancer therapy
  • drug delivery
  • combination therapy
  • lymph node metastasis